NCT06683053View on ClinicalTrials.gov

Evaluation of the Use of Empagliflozin in Patients with HF with PEF in a Cardiology Outpatient Department

PHASE3Active, not recruitingINTERVENTIONAL
Enrollment

90

Participants

Timeline

Start Date

March 17, 2023

Primary Completion Date

April 29, 2024

Study Completion Date

February 28, 2025

Conditions
Congestive Heart Failure (CHF)
Interventions
DRUG

empagliflozin

Comparing the benefits of both doses of empagliflozin (10 mg versus 25 mg) in terms of heart ejection fraction and quality of life.

Trial Locations (1)

89204250

Multidisciplinary Center for Specialized Education and Research Ltd., Joinville

All Listed Sponsors
lead

Conrado Roberto Hoffmann Filho

NETWORK